Intercept to Present at Upcoming Conference
March 16 2017 - 4:05PM
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical
company focused on the development and commercialization of novel
therapeutics to treat progressive non-viral liver diseases, today
announced management will be participating in the following
investor conference:
- Oppenheimer 27th Annual Healthcare Conference on March 21, 2017
at 3:55 p.m. Eastern Time
Webcast information for this event will be
available on the Investors page of Intercept's website at
http://ir.interceptpharma.com. Archived webcasts will be available
on Intercept's website for approximately two weeks.
About InterceptIntercept is a
biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat progressive
non-viral liver diseases, including primary biliary cholangitis
(PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing
cholangitis (PSC) and biliary atresia. Founded in 2002 in New York,
Intercept now has operations in the United States, Europe and
Canada.
CONTACT:
For more information about Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
Investor inquiries: investors@interceptpharma.com
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Sep 2023 to Sep 2024